NASDAQ:INO - Inovio Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.62 0.00 (0.00 %) (As of 03/26/2019 02:42 AM ET)Previous Close$3.62Today's Range$3.51 - $3.6952-Week Range$3.02 - $6.30Volume1.30 million shsAverage Volume1.35 million shsMarket Capitalization$353.44 millionP/E Ratio-3.45Dividend YieldN/ABeta1.72 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc., Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency, and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. Receive INO News and Ratings via Email Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INO Previous Symbol CUSIPN/A CIK1055726 Webwww.inovio.com Phone267-440-4200Debt Debt-to-Equity RatioN/A Current Ratio2.49 Quick Ratio2.49Price-To-Earnings Trailing P/E Ratio-3.45 Forward P/E Ratio-3.42 P/E GrowthN/A Sales & Book Value Annual Sales$30.48 million Price / Sales11.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book3.98Profitability EPS (Most Recent Fiscal Year)($1.05) Net Income$-96,970,000.00 Net Margins-318.11% Return on Equity-93.39% Return on Assets-65.26%Miscellaneous Employees278 Outstanding Shares97,636,000Market Cap$353.44 million Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions What is Inovio Pharmaceuticals' stock symbol? Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO." When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work? Inovio Pharmaceuticals's stock reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split. How were Inovio Pharmaceuticals' earnings last quarter? Inovio Pharmaceuticals Inc (NASDAQ:INO) posted its quarterly earnings results on Tuesday, March, 12th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.03. The biopharmaceutical company earned $2.50 million during the quarter, compared to analyst estimates of $2.69 million. Inovio Pharmaceuticals had a negative return on equity of 93.39% and a negative net margin of 318.11%. During the same quarter in the prior year, the firm earned ($0.23) earnings per share. View Inovio Pharmaceuticals' Earnings History. When is Inovio Pharmaceuticals' next earnings date? Inovio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Inovio Pharmaceuticals. What price target have analysts set for INO? 4 equities research analysts have issued 1 year price targets for Inovio Pharmaceuticals' stock. Their predictions range from $8.00 to $13.00. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $9.6667 in the next year. This suggests a possible upside of 167.0% from the stock's current price. View Analyst Price Targets for Inovio Pharmaceuticals. What is the consensus analysts' recommendation for Inovio Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inovio Pharmaceuticals. What are Wall Street analysts saying about Inovio Pharmaceuticals stock? Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock: 1. HC Wainwright analysts commented, "916-3963, Probability of success (POS) Prob-adj Value Full value S/O as of POLT, U.S. 10% $0.03 $0.34 Shares outstanding 33,165 Emricasan for cirrhosis, U.S." (3/22/2019) 2. According to Zacks Investment Research, "Inovio incurred wider-than-expected loss in Q4. Moreover, revenues missed estimates. The company’s progress with its lead pipeline candidate, VGX-3100, for the treatment of cervical dysplasia is encouraging. Apart from VGX-3100, Inovio also has some promising vaccine candidates in its portfolio, which are progressing well. Additionally, Inovio has collaboration with big pharma companies like Roche, Regeneron and AstraZeneca, which helps the company with their expertise for further growth. Moreover, the company’s targeted cervical cancer market holds untapped potential. However, the company has no approved product in its portfolio and its excessive dependence on its partners for funding the development of its pipeline candidates raises a concern. Shares of the company have underperformed the industry so far this year." (3/15/2019) 3. Maxim Group analysts commented, "Inovio announced the publication of a preclinical study highlighting the successful development of optimized DNA-encoded monoclonal antibodies (dMABs) targeting the immune checkpoint PD-1." (1/15/2019) Has Inovio Pharmaceuticals been receiving favorable news coverage? Media stories about INO stock have been trending positive on Tuesday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Inovio Pharmaceuticals earned a news impact score of 2.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. Are investors shorting Inovio Pharmaceuticals? Inovio Pharmaceuticals saw a increase in short interest in February. As of February 28th, there was short interest totalling 9,393,180 shares, an increase of 34.0% from the February 15th total of 7,010,111 shares. Based on an average daily trading volume, of 1,848,721 shares, the short-interest ratio is presently 5.1 days. Approximately 10.5% of the shares of the stock are short sold. View Inovio Pharmaceuticals' Current Options Chain. Who are some of Inovio Pharmaceuticals' key competitors? Some companies that are related to Inovio Pharmaceuticals include Cardiovascular Systems (CSII), K2M Group (KTWO), AtriCure (ATRC), Luminex (LMNX), Orthofix Medical (OFIX), Tactile Systems Technology (TCMD), Cryolife (CRY), Intersect ENT (XENT), Cerus (CERS), AngioDynamics (ANGO), OraSure Technologies (OSUR), Orthopediatrics (KIDS), Axonics Modulation Technologies (AXNX), LeMaitre Vascular (LMAT) and SurModics (SRDX). What other stocks do shareholders of Inovio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Opko Health (OPK), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Bausch Health Companies (BHC), Micron Technology (MU), Cara Therapeutics (CARA) and NVIDIA (NVDA). Who are Inovio Pharmaceuticals' key executives? Inovio Pharmaceuticals' management team includes the folowing people: Dr. J. Joseph Kim, CEO, Pres & Director (Age 50)Mr. Peter D. Kies, Chief Financial Officer (Age 56)Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 58)Dr. Laurent M. Humeau, Chief Scientific OfficerBen Matone, Director of Investor Relations Who are Inovio Pharmaceuticals' major shareholders? Inovio Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.61%), D. E. Shaw & Co. Inc. (1.13%), Northern Trust Corp (1.10%), Geode Capital Management LLC (1.05%), Geode Capital Management LLC (1.05%) and Dimensional Fund Advisors LP (0.77%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Peter Kies and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals. Which institutional investors are selling Inovio Pharmaceuticals stock? INO stock was sold by a variety of institutional investors in the last quarter, including Virtus ETF Advisers LLC, Millennium Management LLC, MetLife Investment Advisors LLC, New York State Common Retirement Fund, Emerald Advisers LLC, Bank of America Corp DE, Barclays PLC and Principal Financial Group Inc.. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jong Joseph Kim, Peter Kies and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals. Which institutional investors are buying Inovio Pharmaceuticals stock? INO stock was purchased by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Defender Capital LLC., BlackRock Inc., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Geode Capital Management LLC, Geode Capital Management LLC and American Century Companies Inc.. View Insider Buying and Selling for Inovio Pharmaceuticals. How do I buy shares of Inovio Pharmaceuticals? Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Inovio Pharmaceuticals' stock price today? One share of INO stock can currently be purchased for approximately $3.62. How big of a company is Inovio Pharmaceuticals? Inovio Pharmaceuticals has a market capitalization of $353.44 million and generates $30.48 million in revenue each year. The biopharmaceutical company earns $-96,970,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Inovio Pharmaceuticals employs 278 workers across the globe. What is Inovio Pharmaceuticals' official website? The official website for Inovio Pharmaceuticals is http://www.inovio.com. How can I contact Inovio Pharmaceuticals? Inovio Pharmaceuticals' mailing address is 660 WEST GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected] MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 523 (Vote Outperform)Underperform Votes: 321 (Vote Underperform)Total Votes: 844MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: Why are gap-down stocks important?